Sun Pharma receives favorable court ruling in Lipitor patent settlement case in US
Sun Pharma wins US court ruling in Lipitor patent settlement case, ending long-running antitrust litigation.Summary
Sun Pharmaceutical Industries announced a favorable court ruling in the US antitrust litigation concerning the 2008 Pfizer-Ranbaxy patent settlement for generic Lipitor (atorvastatin). The US Court of Appeals for the Third Circuit affirmed the District Courts' summary judgment in favor of Sun Pharma and its subsidiaries, also denying class certification to plaintiffs. The company stated this decision significantly advances the closure of the litigation, subject to any further legal remedies. The ruling resolves a long-standing legal issue following Sun Pharma's 2014 acquisition of Ranbaxy. Additionally, Sun Pharma reported a 27.04% increase in Q1 FY27 net profit to Rs 2,894.79 crore, with revenue rising 10.14% YoY to Rs 15,183.55 crore.
(Source：Business Standard)